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Editorial on the Research Topic
Advances in Early Onset Epilepsies
Early-onset epilepsies (EOE) elicited submissions reflecting the epidemiology, investigation, and
management of these challenging epilepsies: key areas where there has been a significant upshift
in investigation, including genomic, radiological, and electrophysiological technological advances
and targeted therapies.
The genomic investigation of infantile and childhood epileptic encephalopathies has been
transformed initially by gene panels and more recently by whole genome sequencing of both
parents and child (trio). The power of this technology is demonstrated in the paper submitted
from Kazakhstan—the first publication on genomic investigations in children with epilepsies
from Central Asia.
Jaxybayeva et al. described the incidence and prevalence of early-onset epilepsies in their
country. They identified children where gene panel investigation was undertaken and noted that
in up to 80% the result was transformational. On a less positive note, they highlight genomic
sequencing was unavailable to them within Central Asia, and sample analysis abroad meant they
were unable to control the quality/accuracy of the reports. Their call for action within this area is
timely and supported by their data.
Conversely, the Kenyan series of neuroimaging in children with epilepsy highlights the
possibilities within both resource-rich and resource-poor countries. Samia et al. highlight that
up to one-third of the children who underwent an MRI had a positive yield for abnormal
findings. Their cohort was in contradistinction to the etiology of other studies performed
in similar settings, with relatively few cases of infectious etiology. They cross-correlated with
comorbidity/epileptiform activity and suggested appropriate prioritization/ranking for children
undergoing further investigation.
The role of neuromonitoring in neonatal-onset epileptic encephalopathy is a reflection
of practice within well-resourced health environments. Trollmann emphasizes the use of
both standard/amplitude-integrated EEG in monitoring and etiological identification of rare
genetic syndrome.
Taken together, these papers tell us that the investigation of EOE needs to be multi-axial, using
up-to-date technology to allow for accurate classification and hence targeted therapy. This can be
achieved in both resource-poor and resource-rich countries.
The epidemiology of epilepsies is well-covered by two papers covering both rare epilepsies and
also a large national cohort.
Stülpnagel et al. present a very large series of children identified through the network for therapy
and rare epilepsies (NETRE). The power of larger-scale population capture is well-demonstrated
both within the identification of relatively new epilepsy syndromes, e.g., febrile infection-related
epilepsy syndrome (FIRES), classification of different genomic variants, e.g., SCN2A, and both
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clinical features in certain epilepsy syndromes as well as their
investigation findings giving a hallmark of the underlying
etiology, e.g., the MRI findings in FOXG1.
Gibaud et al. synchronized with the NETRE study showing
that studying large cohorts, in this case data from a French
cohort/review of the literature on pyridoxine/pyridoxal
phosphate-dependant epilepsies, concluding that their
consideration is not needed in de novo West Syndrome
(with no other signs or suggestive history). Their data is highly
informative and is likely to simplify the therapeutic journey for
these children from within France and further afield.
Refractory status epilepticus is a relatively rare occurrence,
but often devastating. The papers by Schoeler et al. and Breu
et al. highlight the great challenges but also potential solutions,
including the early introduction of the ketogenic diet. The
papers also highlight the difficulty in extrapolating data from
retrospective case series. Controlled trials of interventions in
very rare conditions in the ICU are very difficult to set up, but
networks of care, such as NETRE, are a possible solution.
The paper by Assenza et al. targets symptom-specific therapy
as opposed to the syndrome. Their case series and systematic
review cover the role of a newer antiepileptic drug in cortical
myoclonus, and they produce an evidence base for therapy of
what are normally extremely challenging epilepsies.
However, many of the epilepsies described, despite benefiting
from accurate classification and disease-specific therapy, will
continue to be drug-resistant and require a high level of support
in all societies.
Taken together, it is a very exciting time in the field
of EOE. These papers reflect the enormous advances
in most settings as well as the challenges that face
us still.
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